HK Stock Market Move | CSTONE PHARMA-B (02616) surged over 4% in early trading. Sales increased significantly after pralsetinib was included in the medical insurance list, with revenue skyrocketing more than three times in the first half of the year.

CSTONE PHARMA-B (02616) rose over 4% in early trading. As of the time of writing, it was up 4.73%, trading at HKD 5.975, with a turnover of HKD 11.5288 million. On the news front, CStone Pharmaceuticals released its interim results, reporting a revenue of RMB 205 million for the first half of the year, a year-on-year increase of 314.75%. Of this, drug sales contributed RMB 183 million, primarily from Pralsetinib, Avapritinib, and Sugemalimab. Following its inclusion in the national medical insurance catalog in January 2026, Pralsetinib's hospital sales surged nearly 500% year-on-year by July 2026, becoming a major driver of revenue growth. Notably, the Hang Seng Index Company recently announced the results of its quarterly review, in which CSTONE PHARMA-B was included in the Hang Seng Composite Index. Changes to the Hang Seng Composite Index will take effect after the market close on September 4 and will be effective from September 7. At that time, the Shanghai and Shenzhen exchanges will adjust the range of investable stocks for the Hong Kong Stock Connect. CSTONE PHARMA-B may be added to the Hong Kong Stock Connect, as it meets a series of criteria including market capitalization and liquidity.